Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache
This clinical trial provides Class I evidence that eptinezumab with patient education is superior to placebo with patient education in reducing MMDs in adults with CM and MOH.
Authors
- Aurélia Mittoux (ORCID: https://orcid.org/0000-0003-2449-807X)
- Mette Krog Josiassen
- M. Lanteri-Minet
- Andrew Blumenfeld (ORCID: https://orcid.org/0000-0003-0851-4914)
- Anders Ettrup (ORCID: https://orcid.org/0000-0002-8926-3012)
- Henrik Winther Schytz (ORCID: https://orcid.org/0000-0002-6262-2986)
- Fabrizio Vernieri (ORCID: https://orcid.org/0000-0002-9594-9336)
- Gary Jansson
- Christofer Lundqvist
- Gisela M. Terwindt
- Stewart J. Tepper
- Cristina Tassorelli
- Rigmor Højland Jensen
- Richard B. Lipton
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Lundbeck (Denmark) (DK)
- Inserm (FR)
- Università Campus Bio-Medico (IT)
- University of Oslo (NO)
- University of Pavia (IT)
- Leiden University Medical Center (NL)
- Akershus University Hospital (NO)
- Glostrup Hospital (DK)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Nice (FR)
- University of Clermont Auvergne (FR)
- New England Institute for Neurology and Headache (US)
- Campus Bio Medico University Hospital (IT)
- COPE Health Solutions (US)
Publication Details
- Journal
- Neurology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1212/wnl.0000000000214863
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00